Filtered By:
Drug: Vytorin

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 235 results found since Jan 2013.

RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus
AbstractDiabetic dyslipidemia is characterised by low HDL-C and high triglyceride levels. Unlike the Caucasian population, though LDL-C levels are not very high, there is a preponderance of more atherogenic small, dense LDL particles among Indians. Furthermore, apo B levels are elevated. This, unique ‘atherogenic dyslipidemia’, is frequently encountered in South Asians with diabetes. People with type 2 diabetes are considered to be at high risk for vascular events. Hence, irrespective of other risk factors such as age, male gender, hypertension, family history, smoking, obesity, and polycyst ic ovary syndrome in women,...
Source: International Journal of Diabetes in Developing Countries - April 7, 2022 Category: Endocrinology Source Type: research

Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials
CONCLUSIONS AND RELEVANCE: This study suggests that the benefits and risks of more intensive LDL-C-lowering statin-based therapies for recurrent stroke risk reduction might be more favorable than the benefits and risks of less intensive LDL-C-lowering statin-based therapies, especially for patients with evidence of atherosclerosis.PMID:35188949 | DOI:10.1001/jamaneurol.2021.5578
Source: Atherosclerosis - February 21, 2022 Category: Cardiology Authors: Meng Lee Chun-Yu Cheng Yi-Ling Wu Jiann-Der Lee Chia-Yu Hsu Bruce Ovbiagele Source Type: research

Intracranial Hemorrhage in the TST Trial
CONCLUSIONS: Targeting an LDL cholesterol of <70 mg/dL compared with 100±10 mg/dL in patients with atherosclerotic ischemic stroke nonsignificantly increased the risk of ICH. Incident ICHs were not associated with low LDL cholesterol. Uncontrolled hypertension and anticoagulant therapy were associated with ICH which has important clinical implications.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01252875; EUDRACT identifier: 2009-A01280-57.PMID:34963300 | DOI:10.1161/STROKEAHA.121.035846
Source: Atherosclerosis - December 29, 2021 Category: Cardiology Authors: Pierre Amarenco Jong S Kim Julien Labreuche Hugo Charles Maurice Giroud Philippa C Lavall ée Byung-Chul Lee Marie-H élène Mahagne Elena Meseguer Norbert Nighoghossian Philippe Gabriel Steg Éric Vicaut Eric Bruckert Treat Stroke to Target Investigators Source Type: research

Prevalence of and Factors Associated With the Prescription of Fibrates Among Patients Receiving Lipid-Lowering Drugs in Germany
Abstract: Little recent data are available about the patterns of prescription for fibrates in patients followed in primary care practices. Therefore, the goal of this study was to analyze the prevalence of and the factors associated with the use of fibrates among patients receiving lipid-lowering drugs in Germany. The study included patients aged ≥18 years with at least 1 visit to 1 of 1070 general practices in Germany between January and December 2019. Lipid-lowering drugs included statins (without and with ezetimibe) and fibrates. The prevalence of the prescription of fibrates corresponded to the number of patients...
Source: Journal of Cardiovascular Pharmacology - December 1, 2021 Category: Cardiology Tags: Original Article Source Type: research

Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India
Curr Vasc Pharmacol. 2021 Nov 9. doi: 10.2174/1570161119666211109122231. Online ahead of print.ABSTRACTStroke is the second most common cause of death worldwide. The rates of stroke are increasing in less affluent countries predominantly because of a high prevalence of modifiable risk factors. The Lipid Association of India (LAI) has provided a risk stratification algorithm for patients with ischaemic stroke and recommended low density lipoprotein cholesterol (LDL-C) goals for those in a very high risk group and extreme risk group (category A) of <50 mg/dl (1.3 mmol/l) while the LDL-C goal for extreme risk group (catego...
Source: Current Vascular Pharmacology - November 9, 2021 Category: Drugs & Pharmacology Authors: Raman Puri Vimal Mehta S S Iyengar Padma Srivastava Jamal Yusuf Akshaya Pradhan Jeyaraj Durai Pandian Vijay K Sharma P N Renjen A Muruganathan K Mugundhan A V Srinivasan Sadanand Shetty S N Narasingan Devaki R Nair Manish Bansal D Prabhakar Mukul Varma Vi Source Type: research